S&P 500   3,380.16 (+0.18%)
DOW   29,398.08 (-0.09%)
QQQ   234.64 (+0.29%)
S&P 500   3,380.16 (+0.18%)
DOW   29,398.08 (-0.09%)
QQQ   234.64 (+0.29%)
S&P 500   3,380.16 (+0.18%)
DOW   29,398.08 (-0.09%)
QQQ   234.64 (+0.29%)
S&P 500   3,380.16 (+0.18%)
DOW   29,398.08 (-0.09%)
QQQ   234.64 (+0.29%)
Log in

NASDAQ:PBYI - Puma Biotechnology Stock Price, Forecast & News

$12.25
-0.05 (-0.41 %)
(As of 02/17/2020 04:00 PM ET)
Today's Range
$11.96
Now: $12.25
$12.53
50-Day Range
$7.71
MA: $9.64
$14.57
52-Week Range
$6.26
Now: $12.25
$43.90
Volume752,495 shs
Average Volume2.73 million shs
Market Capitalization$477.26 million
P/E RatioN/A
Dividend YieldN/A
Beta1.77
Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care. Its drug candidates include PB272 neratinib (oral) for the treatment of early stage breast cancer, metastatic breast cancer, non-small cell lung cancer, HER2 mutation-positive solid tumors, and HER2-mutated non-amplified breast cancer; and PB272 neratinib (intravenous). Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PBYI
CUSIPN/A
Phone424-248-6500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$251 million
Book Value$0.90 per share

Profitability

Net Income$-113,570,000.00

Miscellaneous

Employees272
Market Cap$477.26 million
Next Earnings Date2/20/2020 (Confirmed)
OptionableOptionable

Receive PBYI News and Ratings via Email

Sign-up to receive the latest news and ratings for PBYI and its competitors with MarketBeat's FREE daily newsletter.


Puma Biotechnology (NASDAQ:PBYI) Frequently Asked Questions

What is Puma Biotechnology's stock symbol?

Puma Biotechnology trades on the NASDAQ under the ticker symbol "PBYI."

How were Puma Biotechnology's earnings last quarter?

Puma Biotechnology Inc (NASDAQ:PBYI) released its quarterly earnings data on Wednesday, November, 6th. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.76) by $0.32. The biopharmaceutical company had revenue of $56.40 million for the quarter, compared to analyst estimates of $60.21 million. Puma Biotechnology had a negative return on equity of 325.89% and a negative net margin of 33.90%. The business's revenue for the quarter was down 9.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.16 earnings per share. View Puma Biotechnology's Earnings History.

When is Puma Biotechnology's next earnings date?

Puma Biotechnology is scheduled to release their next quarterly earnings announcement on Thursday, February 20th 2020. View Earnings Estimates for Puma Biotechnology.

How can I listen to Puma Biotechnology's earnings call?

Puma Biotechnology will be holding an earnings conference call on Thursday, February 20th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

What price target have analysts set for PBYI?

10 Wall Street analysts have issued 12 month price targets for Puma Biotechnology's shares. Their forecasts range from $6.00 to $25.00. On average, they expect Puma Biotechnology's stock price to reach $13.38 in the next twelve months. This suggests a possible upside of 9.2% from the stock's current price. View Analyst Price Targets for Puma Biotechnology.

What is the consensus analysts' recommendation for Puma Biotechnology?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Puma Biotechnology in the last year. There are currently 3 sell ratings, 6 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Puma Biotechnology.

What are Wall Street analysts saying about Puma Biotechnology stock?

Here are some recent quotes from research analysts about Puma Biotechnology stock:
  • 1. According to Zacks Investment Research, "Puma Biotech's only marketed drug Nerlynx is approved for breast cancer in the United States and several other countries. A supplemental new drug application to include data from the NALA study on Nerlynx’s label is under review in the US. If approved, the company can gain access and treat an expanded patient population, which can drive sales higher in the future. Several other studies on Nerlynx targeting different types of breast cancer patients in earlier-line settings are also underway. However, Puma Biotech is totally dependent on Nerlynx for growth. Hence, any regulatory setback for Nerlynx will weigh heavily on the stock. Moreover, Nerlynx sales vary from quarter to quarter due to patient discontinuation, which is a persistent concern. Shares of the company have underperformed the industry in the past year." (1/8/2020)
  • 2. Cowen Inc analysts commented, "Cidara reported 4Q18 financial results yesterday and we spoke w/ mgmt for an update. Phase 3 RESTORE trial of rezafungin in Candidemia/ Invasive Candidiasis was initiated last yr and enrollment rate is reportedly in line w/ expectations. Mgmt guiding for top-line results in mid-2020 (unch). Discussions are still ongoing w/ both EMA and FDA around Phase 3 RESPECT trial in prophylaxis. Mgmt nevertheless guiding for initiation in 1H19. Top-line results from Phase 2 STRIVE B trial likely mid-2019. We assume safety/ efficacy profile similar to STRIVE A. Company reported impressive progress w/ a Cloudbreak Influenza candidate last yr and expects to nominate a development candidate 1Q19. BUY. We acknowledge cash constraints, but believe stock does not adequately reflect value of pipeline." (3/1/2019)
  • 3. Cantor Fitzgerald analysts commented, ": Reiterate OW rating; increasing PT to $57/share. Nerlynx roared in 4Q, and 2019 guidance beats expectations. US Nerlynx sales were $61M vs. $53M consensus. Although gross to net was lower in 4Q, we think that 4Q represents a solid beat, and we saw growth in bottles of 12%. In addition, the company’s 2019 US guidance of $255-280M announced on the call exceeded expectations of $238M. Lastly, the company had its first cash flow positive quarter at ~$8M. Shares have recovered by 59% from their early November lows, but we think that there remains upside to shares from Nerlynx growth. We spoke to management post call and we highlight some of our key takes below." (2/28/2019)

Has Puma Biotechnology been receiving favorable news coverage?

Media headlines about PBYI stock have trended somewhat positive on Monday, InfoTrie Sentiment reports. InfoTrie scores the sentiment of media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Puma Biotechnology earned a coverage optimism score of 1.6 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Puma Biotechnology.

Are investors shorting Puma Biotechnology?

Puma Biotechnology saw a increase in short interest during the month of January. As of January 31st, there was short interest totalling 7,820,000 shares, an increase of 12.4% from the January 15th total of 6,960,000 shares. Based on an average trading volume of 1,760,000 shares, the short-interest ratio is presently 4.4 days. Approximately 23.2% of the shares of the company are short sold. View Puma Biotechnology's Current Options Chain.

Who are some of Puma Biotechnology's key competitors?

What other stocks do shareholders of Puma Biotechnology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Puma Biotechnology investors own include Medivation (MDVN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), First Solar (FSLR), Dynavax Technologies (DVAX), United Continental (UAL), Kite Pharma (KITE), Array Biopharma (ARRY), Freeport-McMoRan (FCX) and Celgene (CELG).

Who are Puma Biotechnology's key executives?

Puma Biotechnology's management team includes the folowing people:
  • Mr. Alan H. Auerbach, Founder, Chairman, Pres, CEO & Sec. (Age 49)
  • Dr. Richard P. Bryce, Chief Medical & Scientific Officer (Age 62)
  • Mr. Steven Lo, Chief Commercial Officer (Age 52)
  • Mr. Charles R. Eyler, Sr. VP of Fin. & Admin. and Treasurer (Age 71)
  • Mr. Maximo F. Nougues, CFO & Principal Accounting Officer (Age 50)

Who are Puma Biotechnology's major shareholders?

Puma Biotechnology's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include State Street Corp (9.00%), Fred Alger Management LLC (4.55%), Palo Alto Investors LP (3.46%), Acadian Asset Management LLC (2.15%), Goldman Sachs Group Inc. (1.97%) and Rice Hall James & Associates LLC (1.31%). Company insiders that own Puma Biotechnology stock include Alan H Auerbach, Charles R Eyler, Douglas M Hunt and Richard Paul Bryce. View Institutional Ownership Trends for Puma Biotechnology.

Which major investors are selling Puma Biotechnology stock?

PBYI stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, Goldman Sachs Group Inc., Candriam Luxembourg S.C.A., Point72 Asset Management L.P., FMR LLC, Rafferty Asset Management LLC, Palo Alto Investors LP and Rice Hall James & Associates LLC. Company insiders that have sold Puma Biotechnology company stock in the last year include Alan H Auerbach, Douglas M Hunt and Richard Paul Bryce. View Insider Buying and Selling for Puma Biotechnology.

Which major investors are buying Puma Biotechnology stock?

PBYI stock was purchased by a variety of institutional investors in the last quarter, including State Street Corp, Acadian Asset Management LLC, Credit Suisse AG, Fred Alger Management LLC, Oxford Asset Management LLP, Renaissance Technologies LLC, Schonfeld Strategic Advisors LLC and Alpine Global Management LLC. View Insider Buying and Selling for Puma Biotechnology.

How do I buy shares of Puma Biotechnology?

Shares of PBYI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Puma Biotechnology's stock price today?

One share of PBYI stock can currently be purchased for approximately $12.25.

How big of a company is Puma Biotechnology?

Puma Biotechnology has a market capitalization of $477.26 million and generates $251 million in revenue each year. The biopharmaceutical company earns $-113,570,000.00 in net income (profit) each year or ($2.99) on an earnings per share basis. Puma Biotechnology employs 272 workers across the globe.View Additional Information About Puma Biotechnology.

What is Puma Biotechnology's official website?

The official website for Puma Biotechnology is http://www.pumabiotechnology.com/.

How can I contact Puma Biotechnology?

Puma Biotechnology's mailing address is 10880 WILSHIRE BOULEVARD SUITE 2150, LOS ANGELES CA, 90024. The biopharmaceutical company can be reached via phone at 424-248-6500 or via email at [email protected]


MarketBeat Community Rating for Puma Biotechnology (NASDAQ PBYI)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  498 (Vote Outperform)
Underperform Votes:  480 (Vote Underperform)
Total Votes:  978
MarketBeat's community ratings are surveys of what our community members think about Puma Biotechnology and other stocks. Vote "Outperform" if you believe PBYI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PBYI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/17/2020 by MarketBeat.com Staff

Featured Article: Cash Flow

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel